Anti Inflammatory News and Research

RSS

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

A key compound resupplies bone marrow with fast-acting stem cells that can more quickly rekindle blood cell production, according to a study published online today in the journal Blood. While the study was in mice, in the study authors say it has the potential to increase survival among patients with life-threatening blood cell shortages.

3 Sep 2009

Pfizer to pay $2.3 billion for health care fraud settlement

American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. (hereinafter together "Pfizer") have agreed to pay $2.3 billion, the largest health care fraud settlement in the history of the Department of Justice, to resolve criminal and civil liability arising from the illegal promotion of certain pharmaceutical products, the Justice Department announced today.

3 Sep 2009

LifeVantage granted third patent for Protandim

LifeVantage Corporation, has been granted a third patent for its flagship product Protandim from the United States Patent and Trademark Office. Protandim has been clinically proven in earlier studies to slow the progressive rate of aging by reducing oxidative stress and this new patent further documents Protandim’s® effect on antioxidant enzymes in vivo, describing anti-inflammatory effects such as the lowering of C-reactive protein.

2 Sep 2009

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a co-operative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany for the preclinical and clinical development of WF10 as a potential treatment for Allergic Rhinitis.

2 Sep 2009

Researchers analyze the role of bioactive lipids in inflammatory diseases

According to the National Center for Chronic Disease Prevention and Health Promotion, 46 million Americans have arthritis. Many of these people take over-the-counter anti-inflammatory medications that block production of certain molecules, known as bioactive lipids, to reduce pain and swelling. Yet, the role of these lipids is not yet understood completely, and medications may have adverse side effects.

2 Sep 2009

New Drug Application for VIMOVO accepted by U.S. Food and Drug Administration

POZEN Inc. (NASDAQ:POZN), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for VIMOVO™ (enteric-coated naproxen / immediate release esomeprazole magnesium, formerly know as PN 400).

31 Aug 2009

Forest Laboratories announces phase 3 trial results for roflumilast

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.

28 Aug 2009

Study reveals effectiveness of BioElectronics' ActiPatch therapy device for treating heel and foot pain

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of an important clinical study on heel and foot pain, which was led by David Genecov, M.D. FACS FAAP.

27 Aug 2009

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.

27 Aug 2009

New technique for diabetes treatment may be in the offing

An exploration of the molecular links between insulin resistance and inflammation may have revealed a novel target for diabetes treatment, say scientists at the John G. Rangos Sr. Research Center, Children's Hospital of Pittsburgh of UPMC. Their findings were published earlier this month in the online version of Diabetes, one of the journals of the American Diabetes Association.

27 Aug 2009

Herbalscience research throws light on causes of allergic rhinitis

Most people might think of nettle as simply a common and aggressive weed that can sting and cause skin irritation. But nettle has also been used for hundreds of years to treat seasonal allergies and other inflammatory diseases, although the precise nature of its anti-inflammatory effect was unknown. Now, scientists with HerbalScience have identified specific bioactives in nettle leaf extracts that inhibit in vitro receptors and enzymes known to be key in generating symptoms of allergic rhinitis, or hay fever.

26 Aug 2009

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

26 Aug 2009

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

Endo Pharmaceuticals announced today the commencement of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary. The purpose of the tender offer is to acquire any and all Notes to reduce the consolidated interest expense of Endo.

26 Aug 2009

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6.

26 Aug 2009

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

26 Aug 2009

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, announced today it has entered into a research collaboration agreement with the PATH Malaria Vaccine Initiative (MVI) to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus (rVSV) vector technology as a preventative malaria vaccine.

26 Aug 2009

Impact Fusion International to commence filming of Anti-Steroids and Anti-Drug Campaign

Impact Fusion International, Inc. (PINKSHEETS: IFUS) announced that it will begin filming of its Anti-Steroids and Anti-Drug Campaign with retired NFL star Kenneth Davidson. This campaign will be centered around the Intact Sports Nutrition products Intact Endurance and Intact Protein+ that will be sold as a system called Intact Complete.

25 Aug 2009

Bioelectronics to sponsor clinical study comparing the effects of ActiPatch to Tylenol for the treatment of muscle pain and soreness

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced it will sponsor a clinical study comparing the effects of ActiPatch® Therapy to Tylenol® for the treatment of muscle pain and soreness.

24 Aug 2009

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.

24 Aug 2009

Study reveals that treating Alzheimer's disease with DHA and EPA slows down its progression

Scientists have identified the inflammatory process as the common soil in a diverse range of chronic degenerative diseases. The news, recently reported in the LA Times article, discusses how foods like cherries may help rheumatoid arthritis or avoidance of gluten may fight off psoriasis.

24 Aug 2009

Anti Inflammatory News and Research

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

Pfizer to pay $2.3 billion for health care fraud settlement

LifeVantage granted third patent for Protandim

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Researchers analyze the role of bioactive lipids in inflammatory diseases

New Drug Application for VIMOVO accepted by U.S. Food and Drug Administration

Forest Laboratories announces phase 3 trial results for roflumilast

Study reveals effectiveness of BioElectronics' ActiPatch therapy device for treating heel and foot pain

Novelos Therapeutics enters into a definitive agreement with Purdue Pharma to raise funds

New technique for diabetes treatment may be in the offing

Herbalscience research throws light on causes of allergic rhinitis

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Peptimmune's Phase Ib clinical trial of PI-2301 in multiple sclerosis patients complete

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Impact Fusion International to commence filming of Anti-Steroids and Anti-Drug Campaign

Bioelectronics to sponsor clinical study comparing the effects of ActiPatch to Tylenol for the treatment of muscle pain and soreness

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Study reveals that treating Alzheimer's disease with DHA and EPA slows down its progression

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News